{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:57:19Z","timestamp":1787029039449,"version":"build-2736575974"},"reference-count":50,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T00:00:00Z","timestamp":1549756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>One of the key stages in the development of new therapies in the treatment of toxoplasmosis is the identification of new non-toxic small molecules with high specificity to Toxoplasma gondii. In the search for such structures, thiosemicarbazide-based compounds have emerged as a novel and promising leads. Here, a series of imidazole-thiosemicarbazides with suitable properties for CNS penetration was evaluated to determine the structural requirements needed for potent anti-Toxoplasma gondii activity. The best 4-arylthiosemicarbazides 3 and 4 showed much higher potency when compared to sulfadiazine at concentrations that are non-toxic to the host cells, indicating a high selectivity of their anti-toxoplasma activity.<\/jats:p>","DOI":"10.3390\/molecules24030614","type":"journal-article","created":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T03:18:20Z","timestamp":1549941500000},"page":"614","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Systematic Identification of Thiosemicarbazides for Inhibition of Toxoplasma gondii Growth In Vitro"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8198-7702","authenticated-orcid":false,"given":"Agata","family":"Paneth","sequence":"first","affiliation":[{"name":"Department of Organic Chemistry, Medical University, Chod\u017aki 4a, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"W\u0119gli\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry, Medical University, Chod\u017aki 4a, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4980-1074","authenticated-orcid":false,"given":"Adrian","family":"Bekier","sequence":"additional","affiliation":[{"name":"Department of Immunoparasitology, Faculty of Biology and Environmental Protection, University of Lodz, Banacha 12\/16, 90-237 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edyta","family":"Stefaniszyn","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry, Medical University, Chod\u017aki 4a, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Wujec","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry, Medical University, Chod\u017aki 4a, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazar","family":"Trotsko","sequence":"additional","affiliation":[{"name":"Department of Organic Chemistry, Medical University, Chod\u017aki 4a, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Dzitko","sequence":"additional","affiliation":[{"name":"Department of Immunoparasitology, Faculty of Biology and Environmental Protection, University of Lodz, Banacha 12\/16, 90-237 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,2,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/S0140-6736(04)16412-X","article-title":"Toxoplasmosis","volume":"363","author":"Montoya","year":"2004","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0020-7519(00)00124-7","article-title":"Toxoplasma gondii: From animals to humans","volume":"30","author":"Tenter","year":"2000","journal-title":"Int. J. Parasitol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1471-4922(02)02248-1","article-title":"Toxoplasma gondii tachyzoite-bradyzoite interconversion","volume":"18","author":"Lyons","year":"2002","journal-title":"Trends Parasitol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00436-010-1899-6","article-title":"Toxoplasma gondii: Determinants of tachyzoite to bradyzoite conversion","volume":"107","author":"Sini","year":"2010","journal-title":"Parasitol. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1021\/ml400208v","article-title":"Discovery of potent and selective inhibitors of Toxoplasma gondii thymidylate synthase for opportunistic infections","volume":"4","author":"Zaware","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1574-6976.2011.00305.x","article-title":"Mechanisms of Toxoplasma gondii persistence and latency","volume":"36","author":"Sullivan","year":"2012","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/clinids\/15.2.211","article-title":"Toxoplasmic encephalitis in AIDS","volume":"15","author":"Luft","year":"1992","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","first-page":"322","article-title":"Toxoplasmosis in the non-AIDS immunocompromised host","volume":"13","author":"Israelski","year":"1993","journal-title":"Curr. Clin. Top Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.ijpara.2008.03.007","article-title":"Toxoplasma gondii infection in humans and animals in the United States","volume":"38","author":"Dubey","year":"2008","journal-title":"Int. J. Parasitol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.actatropica.2018.04.026","article-title":"Current treatment of ocular toxoplasmosis in immunocompetent patients: A network meta-analysis","volume":"185","author":"Zhang","year":"2018","journal-title":"Acta Trop."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.actatropica.2011.10.018","article-title":"Congenital parasitic infections: A review","volume":"121","author":"Carlier","year":"2012","journal-title":"Acta Trop."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"870","DOI":"10.2307\/3284282","article-title":"Oocyst-induced murine Toxoplasmosis: Life cycle, pathogenicity, and stage conversion in mice fed Toxoplasma gondii oocysts","volume":"83","author":"Dubey","year":"1997","journal-title":"J. Parasitol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1359-6446(04)03308-2","article-title":"Targeting DHFR in parasitic protozoa","volume":"10","author":"Anderson","year":"2005","journal-title":"Drug Discov. Today"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1128\/AAC.02009-15","article-title":"Clinically available medicines demonstrating anti-toxoplasma activity","volume":"59","author":"Neville","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Wei, H.X., Wei, S.S., Lindsay, D.S., and Peng, H.J. (2015). A systematic review and meta-analysis of the efficacy of anti-Toxoplasma gondii medicines in humans. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0138204"},{"key":"ref_16","first-page":"1","article-title":"Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Recommendations from CDC, the National Institutes of Health and the HIV Medicine Association of the Infectious Diseases Society of America","volume":"58","author":"Kaplan","year":"2009","journal-title":"CDC MMWR"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"325","DOI":"10.4269\/ajtmh.1984.33.325","article-title":"Synergistic antimalarial activity of pyrimethamine and sulfadoxine against Plasmodium falciparum in vitro","volume":"33","author":"Chulay","year":"1984","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1128\/AAC.32.4.430","article-title":"Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate","volume":"32","author":"Kovacs","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1128\/AAC.35.7.1348","article-title":"Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs","volume":"35","author":"Broughton","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1128\/AAC.37.9.1914","article-title":"Identification of highly potent and selective inhibitors of Toxoplasma gondii dihydrofolate reductase","volume":"37","author":"Chio","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"491","DOI":"10.4269\/ajtmh.1988.39.491","article-title":"Efficacy of trimetrexate, a potent lipid-soluble antifolate, in the treatment of rodent Pneumocystis carinii pneumonia","volume":"39","author":"Kovacs","year":"1988","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1021\/acsinfecdis.8b00113","article-title":"Evaluation of current and emerging antimalarial medicines for inhibition of Toxoplasma gondii growth in vitro","volume":"10","author":"Radke","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"9976","DOI":"10.1021\/acs.jmedchem.7b01192","article-title":"Inhibition of calcium dependent protein kinase 1 (CDPK1) by pyrazolopyrimidine analogs decreases establishment and reoccurrence of central nervous system disease by Toxoplasma gondii","volume":"60","author":"Rutaganira","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Joynson, D.H.M., and Wreghitt, T.G. (2001). Antitoxoplasma chemotherapy. Toxoplasmosis: A Comprehensive Clinical Guide, Cambridge Univ. Press.","DOI":"10.1017\/CBO9780511527005"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"9974","DOI":"10.1021\/acs.jmedchem.7b01663","article-title":"Novel molecules to treat chronic central nervous system Toxoplasmosis","volume":"60","author":"Kortagere","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1128\/AAC.40.6.1360","article-title":"Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii","volume":"40","author":"Jacobson","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s40268-017-0206-8","article-title":"Adverse event profile of pyrimethamine-based therapy in toxoplasmosis: A systematic review","volume":"17","author":"Goodwin","year":"2017","journal-title":"Drugs R&D"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/hiv.12402","article-title":"A systematic review and meta-analysis of the relative efficacy and safety of treatment regimens for HIV-associated cerebral toxoplasmosis: Is trimethoprim-sulfamethoxazole a real option?","volume":"18","author":"Hernandez","year":"2017","journal-title":"HIV Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/B978-0-444-52910-7.00028-3","article-title":"Congenital toxoplasmosis","volume":"112","author":"Kieffer","year":"2013","journal-title":"Handb. Clin. Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1021\/jm950760y","article-title":"Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations","volume":"39","author":"Piper","year":"1996","journal-title":"J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/infdis\/167.2.494","article-title":"The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine","volume":"167","author":"Araujo","year":"1993","journal-title":"J. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/AAC.37.11.2371","article-title":"In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii","volume":"37","author":"Romand","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1128\/AAC.36.2.326","article-title":"In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii","volume":"36","author":"Araujo","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1021\/op500032w","article-title":"A single-pot synthesis of atovaquone: An antiparasitic drug of choice","volume":"18","author":"Dike","year":"2014","journal-title":"Org. Process Res. Dev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.exppara.2012.02.026","article-title":"Toxoplasma gondii: The vaccine potential of three trivalent antigen-cocktails composed of recombinant ROP2, ROP4, GRA4 and SAG1 proteins against chronic toxoplasmosis in BALB\/c mice","volume":"131","author":"Dziadek","year":"2012","journal-title":"Exp. Parasitol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"9926","DOI":"10.3390\/molecules19079926","article-title":"1,4-disubstituted thiosemicarbazide derivatives are potent inhibitors of Toxoplasma gondii proliferation","volume":"19","author":"Dzitko","year":"2014","journal-title":"Molecules"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00894-011-1117-1","article-title":"Problems with molecular mechanics implementations on the example of 4-benzoyl-1-(4-methyl-imidazol-5-yl)-carbonylthiosemicarbazide","volume":"18","author":"Siwek","year":"2012","journal-title":"J. Mol. Model."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lombardo","year":"1997","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_40","unstructured":"(2018, December 20). Logs Calculation. Available online: https:\/\/www.organic-chemistry.org\/prog\/peo\/logS.html."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1023\/A:1020444330011","article-title":"Rate-limited steps of human oral absorption and QSAR studies","volume":"19","author":"Zhao","year":"2002","journal-title":"Pharm. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejmech.2010.11.010","article-title":"Synthesis and antimicrobial activity of thiosemicarbazides, s-triazoles and their Mannich bases bearing 3-chlorophenyl moiety","volume":"46","author":"Plech","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1016\/j.ejmech.2010.05.017","article-title":"Synthesis and evaluation of anti-Toxoplasma gondii and antimicrobial activities of thiosemicarbazides, 4-thiazolidinones and 1,3,4-thiadiazoles","volume":"45","author":"Liesen","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/hc.20643","article-title":"Study of direction of cyclization of 1-azolyl-4-aryl\/alkyl-thiosemicarbazides","volume":"21","author":"Siwek","year":"2010","journal-title":"Heteroatom Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.1016\/j.ejmech.2011.09.034","article-title":"Synthesis and structure-activity relationship studies of 4-arylthiosemicarbazides as topoisomerase IV inhibitors with Gram-positive antibacterial activity. Search for molecular basis of antibacterial activity of thiosemicarbazides","volume":"46","author":"Siwek","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jep.2005.12.005","article-title":"Ethnopharmacological evaluation of the informant consensus model on anti-tuberculosis claims among the Manus","volume":"106","author":"Case","year":"2006","journal-title":"J. Ethnopharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bjp.2016.08.002","article-title":"Bioassay-guided fractionation and antimicrobial and cytotoxic activities of Cassia bakeriana extracts","volume":"27","author":"Cunha","year":"2017","journal-title":"Rev. Bras. Farmacogn."},{"key":"ref_48","unstructured":"(2007). Hyperchem 8.0.3, HyperCube Inc."},{"key":"ref_49","unstructured":"(2018, December 20). Calculation of Molecular Physicochemical Properties\u2014Molinspiration. Available online: http:\/\/www.molinspiration.com\/cgi-bin\/properties."},{"key":"ref_50","unstructured":"(2018, December 20). On-line Software\u2014VCCLab. Available online: http:\/\/www.vcclab.org\/online.html."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/3\/614\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:30:55Z","timestamp":1760185855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/24\/3\/614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,10]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,2]]}},"alternative-id":["molecules24030614"],"URL":"https:\/\/doi.org\/10.3390\/molecules24030614","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,10]]}}}